HIV treatment strategies utilizing virologic and immunologic markers as criteria for changing treatments

Statistics in Medicine

Volumn 15, Issue 21-22, 1996, Pages 2425-2443

  Elashoff, Michael ^a   Lagakos, Stephen ^b  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

CONFERENCE PAPER; DISEASE COURSE; DRUG COMBINATION; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOREACTIVITY; MODEL; PRACTICE GUIDELINE; SURVIVAL; VIROLOGY;

EID: 0029969748     PISSN: 02776715     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0258(19961130)15:22<2425::aid-sim461>3.0.co;2-d     Document Type: Conference Paper

References (14)

1. Volberding, P. 'The need for additional options in the treatment of human immunodeficiency virus infection', The Journal of Infectious Diseases, bf 171, (Suppl 2), S150-154 (1995).
2. Cheeseman, S., Havlir, D., McLaughlin, M., Greenough, T., Sullivan, J., Hall, D., Hatfox, S., Spector, S., Stein, D., Myers, M. and Richman, D. 'Phase I/II evaluation of Nevirapine alone and in combination with Zidovudine for infection with human immunodeficiency virus', Journal of Acquired Immune Deficiency Syndromes, 8, 141-151 (1995).
3. Cooper, D. 'Early antiretroviral therapy', AIDS, 8, (Suppl 3), S9-14 (1994).
4. Kozal, M., Shafer, R., Winters, M., Katzenstein, O., Aguiniga, E., Halpern, J. and Merigan, T. 'HIV-1 syncytium-inducing phenotype, virus burden, codon 215 reverse transcriptase mutation and CD4 cell decline in zidovudine-treated patients', Journal of Acquired Immune Deficiency Syndromes, 7, 832-838 (1994).
5. Wainberg, M., Salomon, M., Gu, Z., Montaner, J., Cooley, T., McCaffrey, R., Ruedy, J., Hirst, H., Cammack, N., Cameron, J. and Nicholson, W. 'Development of HIV-1 resistance to (-)2′-deoxy-3′-thiacytidine in patients with AIDS or advanced AIDS-related complex', AIDS, 9, 351-357 (1995).
6. Moss, R., Ferré, F., Trauger, R., Jensen, F., Daigle, A., Richieri, S. and Carlo, D. 'Inactivated HIV-1 immunogen: impact on markers of disease progression', Journal of Acquired Immune Deficiency Syndromes, 7, (Suppl 1), S21-27 (1994).
7. Richman, D., Meng, T., Spector, S., Fischl, M., Resnick, L. and Lai, S. 'Resistance to AZT and ddC during long-term combination therapy in patients with advanced infection with human immunodeficiency virus', Journal of Acquired Immune Deficiency Syndromes, 7, 135-138 (1994).
8. D'Aquila, R., Johnson, V., Welles, S., Japour, A., Kuritzkes, D., DeGruttola, V., Reichelderfer, P., Coombs, R., Crumpacker, C., Kahn, J. and Richman, D. 'Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy', Annals of Internal Medicine, 122, 401-408 (1995).
9. Mellors, J., Larder, B. and Schinazi, R. 'Mutations in HIV-1 reverse transcriptase and protease associated with drug resistance', unpublished (1994).
10. Volberding, P., Lagakos, S., Grimes, J., Stein, D., Rooney, J., Meng, T., Fischl, M., Collier, A., Phair, J. and Hirsch, M. 'A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter', New England Journal of Medicine, 333, 401-407 (1995).
11. Saag, M. 'Report from the 2nd International Congress on Drug Therapy in HIV Infection', HIV Information Network Fax Newsletter, 29 November (1994).
12. Richman, D., Grimes, J. and Lagakos, S. 'Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus', Journal of Acquired Immune Deficiency Syndromes, 3, 743-746 (1990).
13. Graham, N., Piantadosi, S., Park, L., Phair, J., Rinaldo, C. and Fahey, J. 'CD4+ lymphocyte response to zidovudine as a predictor of AIDS-free survival time and survival time', Journal of Acquired Immune Deficiency Syndromes, 6, 1258-1266 (1993).
14. Masquelier, B., Pellegrin, I., Ruffault, A., Ragnaud, S., Marlat, P., Michelet, C., Doignon, F., Biteau, N. and Fleury, H. 'Genotypic evolution of HIV-1 isolates from patients after a switch of therapy from zidovudine to didanosine', Journal of Acquired Immune Deficiency Syndromes, 8, 330-334 (1995).